Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TLR4 | O00206 | 9/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336925 | 1.00 | MAPT (0.46) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL2335538 | 0.93 | MAPT (0.48) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL2335548 | 0.93 | MAPT (0.48) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL17453047 | 0.93 | MAPT (0.48) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL17453045 | 0.93 | MAPT (0.48) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL2339111 | 0.93 | MAPT (0.48) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL17453046 | 0.93 | MAPT (0.48) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL2338095 | 0.88 | TLR4 (0.53) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL2343353 | 0.88 | TLR4 (0.53) | MAPTTLR4LMNAKMT2ALY96 | |
| SCHEMBL2338089 | 0.88 | TLR4 (0.53) | MAPTTLR4LMNAKMT2ALY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151400-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | UNIV JOHNS HOPKINS (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067960-B2 | Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-30 | — | — | US | disclosed |
| US-8916544-B2 | Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20110206734-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | MAPT 2222/4885TLR4 704/4885LMNA 1218/4885 |
| US-20160151400-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | MAPT 2222/4885TLR4 704/4885LMNA 1218/4885 |
| US-20110206734-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | MAPT 2222/4885TLR4 704/4885LMNA 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.